In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Maintenance of gains, morbidity and mortality one-year following cardiac rehabilitation in a middle-income country: a wait-list control crossover trial

Session Poster Session 2

Speaker Raquel Rodrigues Britto

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P525

Authors : G Chaves (Belo Horizonte,BR), G Ghisi (Toronto,CA), R Britto (Belo Horizonte,BR), S Grace (Toronto,CA)

Authors:
G Chaves1 , G Ghisi2 , R Britto1 , S Grace3 , 1Federal University of Minas Gerais - Belo Horizonte - Brazil , 2UHN - University of Toronto - Toronto - Canada , 3York University - Toronto - Canada ,

Citation:

Background: Cardiovascular diseases are among the leading burdens of disease globally, and are the leading cause of death, with >80% of these deaths occurring in low and middle-income countries, such as Brazil. Despite the epidemic of cardiovascular diseases in middle-income countries (MICs), there are few trials testing the benefits of cardiac rehabilitation (CR).Reduced mortality and morbidity in the long-term are likely achieved through maintenance of heart-health behavior changes initiated through CR, which ensures sustained risk factor control. Purpose:This trial assessed: (1) maintenance of functional capacity, risk factor control, knowledge and heart-health behaviors, as well as (2) mortality and morbidity 6 months following CR in a MIC. Methods:Eligible Brazilian coronary patients were initially randomized (1:1:1 concealed) to one of three parallel arms (comprehensive CR [exercise + education] vsexercise-only CR vswait-list control). The CR programs were six months in duration, at which point follow-up assessment was performed. Mortality and morbidity were ascertained from chart and patient/family-report (blinded). Controls were then offered CR. Outcomes were again assessed 6 months later (blinded). Analysis of covariance (ANCOVA) was performed for each outcome at 12 months.Results: 115 (88.5%) patients were randomized; 62 (53.9%) were retained at 1 year. At 6 months, of those 39 initially randomized to the wait-list control, 23 (58.9%) elected to attend CR. Functional capacity, risk factors, knowledge and heart-health behaviorswere maintained from 6-12 months in participants from both CR arms (all p>.05). At 1 year, there was significantly greater knowledge with CCR at either time point (p<.001). There were only two deaths. There were significantly fewer hospitalizations (p=.03), non-fatal myocardial infarctions (p=.04), and percutaneous coronary interventions (p=.03) with CR than control at 6-months.

Conclusions: CR participation is associated with lower morbidity, long-term maintenance of functional capacity, risk factors and heart-health behaviours as well as greater CV knowledge when compared to no CR.

Trial registration: Clinical Trials, NCT02575976. Registered 14 October 2015 (https://clinicaltrials.gov/show/NCT02575976).



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are